We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 192

Boots on the Ground: PIL Task Force Targeting Opioid Providers in the War on Drugs
  • K&L Gates
  • USA
  • April 30 2018

Attorney General Jeff Sessions announced the creation of the Prescription Interdiction & Litigation (“PIL”) Task Force -- which Sessions described as


FDA Releases Flurry of Compounding-Related Documents
  • Quarles & Brady LLP
  • USA
  • July 19 2016

Busy, busy, busy! That is the only way to describe the FDA over the past few weeks, issuing multiple draft guidance documents affecting both 503A and


FDA again delays Drug Product tracing obligations for Dispensers (including pharmacies and physician offices) to March 1, 2016
  • Hall Render Killian Heath & Lyman PC
  • USA
  • November 2 2015

On October 28, 2015, the Food and Drug Administration (“FDA”) revised its June 30, 2015 guidance delaying the enforcement of key track and trace


Reducing spending and raising the debt ceiling - just the beginning
  • Faegre Baker Daniels LLP
  • USA
  • August 11 2011

The recently enacted Budget Control Act of 2011, which permitted the United States to raise its debt ceiling, includes complex new mechanisms to control spending and reduce the federal deficit.


Pharmacists and the learned intermediary rule
  • Dechert LLP
  • USA
  • February 24 2011

As our readers certainly know, the learned intermediary rule holds that prescription medical product warnings are to be directed to prescribing physicians rather than to end user patients.


Health reform bills include Physician Payment Sunshine provisions
  • Foley & Lardner LLP
  • USA
  • November 16 2009

Among the myriad of proposals for health care reform are some familiar provisions that are intended to increase the transparency of relationships between device and pharmaceutical manufacturers and physicians (and some others).


Health reform bills include physician payment sunshine provisions
  • Foley & Lardner LLP
  • USA
  • November 12 2009

Among the myriad of proposals for health care reform are some familiar provisions that are intended to increase the transparency of relationships between device and pharmaceutical manufacturers and physicians (and some others).


Health policy legislation moves through Congress
  • Reed Smith LLP
  • USA
  • October 1 2008

There has been a flurry of recent legislative activity as the 110th Congress prepares to adjourn in the coming days.